This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Pfizer Inc.
Reference
Baker CL, et al. A cost-benefit analysis of smoking cessation prescription coverage from a US payer perspective. ClinicoEconomics and Outcomes Research : 16 Jul 2018. Available from: URL: https://doi.org/10.2147/CEOR.S165576
Rights and permissions
About this article
Cite this article
Smoking cessation prescription coverage good investment in US. PharmacoEcon Outcomes News 808, 28 (2018). https://doi.org/10.1007/s40274-018-5143-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5143-4